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PHARMACY
Drug - Drug Interaction-A case Report
Dr Mahreen Muzzamil, Pharmacist
60 year old female presented to ER with complain of head and neck 
pain which subsided after naproxen 500mg BID. The hypertension was 
managed by nitroglycerine infusion. During rounds next day it was 
identified that 3 doses of amlodipine 5mg and 2 doses of losartan 50mg 
was not enough to decrease the blood pressure. A third agent, bisoprolol 
was added without any significant result. The clinical pharmacist pointed 
out an interaction that naproxen and ACE inhibitors/Angiotensin receptor 
blockers cause an increase in blood pressure. Naproxen was discontinued 
and hypertension was controlled with amlodipine 5mg BID and losartan 
50mg QD 
Naproxen is an NSAIDs. It may decrease the antihypertensive 
(probable mechanism: additive effects on renal function; decreased 
renal prostaglandin production) and natriuretic effect of ACE inhibitors 
or angiotensin receptor blockers (ARBs). When concomitant use is 
required, monitor for antihypertensive efficacy and assess renal function 
periodically for signs of renal deterioration or failure especially in patients 
who are elderly, volume-depleted, or with preexisting renal dysfunction.
References:
	 l FDA Center for Drug Evaluation Research. FDA draft guidance for industry: 
  drug interaction studies—study design, data analysis, implications for dosing,   
  and labeling recommendations. 2012.
	 l Kurata C, Uehara A, Sugi T et al: Syncope caused by nonsteroidal anti-inflam  
  matory drugs and angiotensin-converting enzyme inhibitors. Jpn Circ J 1999;   
  63:1002-1003.
Differential Diagnosis of Increased Cardiac 
Troponin Levels
Dr Kashif Hussain, Infectious disease, Specialist
Cardiac troponin (cTn) testing is an essential component of the diagnostic 
workup and management of acute coronary syndromes (ACS). Although 
over the past 15 years the diagnostic performance of the previous gold-
standard assay, creatine kinase-MB, has not changed appreciably, the ever-
increasing sensitivity of cTn assays has had a dramatic impact on the use 
of cTn testing to diagnose ACS. 
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Causes of elevated Plasma Cardiac Troponin Other Than Acute Coronary Syndromes.
l Cardiac contusion resulting from  
 trauma
l Cardiac surgery
l Cardio-version
l Endomyocardial biopsy
l Acute and chronic heart failure
l Aortic dissection
l Myocarditis or endocarditis /
 pericarditis
l Aortic valve disease
l Hypertrophic cardiomyopathy
l Tachyarrhythmia
l Brady-arrhythmia, heart block
l Apical ballooning syndrome
l Post–percutaneous coronary 
 intervention
l Rhabdomyolysis with myocyte  
 necrosis
l Pulmonary embolism
l Severe pulmonary hypertension
l Renal failure
l Stroke, subarachnoid hemorrhage
l Infiltrative diseases, e.g., amyloidosis
l Cardio-toxic drugs
l Critical illness
l Sepsis
l Extensive burns
l Extreme exertion
Cardiac Causes Non-cardiac Causes
References:
 l Melanson SEF, Morrow DA, Jarolim P Earlier detection of myocardial injury in a preliminary evaluation using a new  
  troponin I assay with improved sensitivity. Am J Clin Pathol. 2007;128:282–286.
	 l Jaffe AS, Babuin L, Apple FS Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 
  2006; 48:1–11.
Survey on Knowledge and Awareness of Pharmacists about Venous 
Thromboembolism and Anticoagulation in Pakistan
Sumaira Khan, Specialist
Venous thromboembolism (VTE) is considered to be the most common preventable cause of hospital-related 
deaths. Hospitalized patients undergoing major surgeries and those with acute medical illness are at an 
increased risk of VTE. Since management of VTE is multidisciplinary, it is critical that pharmacists should have 
adequate understanding of the anticoagulation. Studies reported 60% of VTE cases occur during or following 
hospitalization. VTE is negated agenda in the region which requires awareness among not only pharmacist but 
Physicians and nurses as well. Purpose of this cross sectional study the was to investigate pharmacists’ awareness 
and knowledge of VTE, and perioperative management of anti-coagulated patients in a hospital.
All pharmacists agreed that VTE prophylaxis is clinically important, , 75% pharmacists were aware of 
institutional policy for thromboprophylaxis, 95% agreed that their institute should have peri-operative 
guidelines available for safe care, 100% agreed that pharmacists can play important role in VTE guideline 
development in their institutes, only 33% pharmacists were aware of perioperative management of heparin, 
only 52% were aware of appropriate use of DVT prophylaxis in hospitalized patients, 53.66% knew that 
patients can develop DVT after discharge, only 34.15%  aware of VTE occurrence  within 90 days of 
hospitalization  in majority of hospitalized patients.
Pharmacists can also play a key role in helping hospitals achieve performance measures by aiding in the 
development and implementation of local VTE guidelines, policies, and other quality improvement initiatives 
providing valuable education for other health care professionals like doctors, Nurses and patients alike.
Reference: 
	 l Dobesh PP, Trujillo TC, Finks SW. Role of the pharmacist in achieving performance measures to improve the prevention 
  and treatment of venous thromboembolism. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 
  2013 Jun 1;33(6):650-64.
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*Drugs are the part of AKUH Formulary supported by National AIDs Control Program (NACP).
Reference:
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Due to the risk of postnatal transmission of HIV, the Centers for 
Disease Control and Prevention does not recommend breastfeed-
ing for HIV-infected mothers, including those who are receiving 
combination antiretroviral therapy or prophylaxis.
Antiretroviral (HIV) Drugs
Drug Pregnancy Risk Category Lactation Status
Pregnancy Risk & Lactation Safety of Antiretroviral (HIV)
Dr Shayan Ahmed, Pharmacist
The U.S. Food and Drug Administration (FDA) categorizes pregnancy risk in 5 categories: 
 l A =  Adequate studies in pregnant women, no risk 
	 l B =  Animal reproduction studies, no fetal risk; no controlled studies in pregnant women 
	 l	 C =  Animal reproduction studies have shown fetal adverse effect; no controlled studies in 
          humans; potential benefit may warrant use despite potential risk 
	 l D =  Evidence of human fetal risk; potential benefit may warrant use despite potential risk 
	 l	 X =  Animal and human studies demonstrate fetal abnormalities; risks in pregnant women clearly 
   exceed potential benefits
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The Aga Khan University Hospital, Karachi
Provide us your Valuable Feedback!
To keep the Pharmacy Newsletter of Aga Khan University Hospital (AKUH) updated we would like to take your valuable feedback. We are grateful 
to you for sparing few minutes of your precious time to complete form by below online link or form can be emailed to you as well. Just drop us an 
email with subject Newsletter Feedback. Email us at:drug.information@aku.edu 
Thank you in advance for your feedback! 
Link: 
https://goo.gl/forms/Ghh1Nc2KY2jEkiUL2
Polypill Drug Concept - Primary Prevention of Cardiovascular Disease
Dr Ale Zehra, Clinical Pharmacist
Non-communicable disease (NCDs) contribute globally two-thirds of all deaths. Cardiovascular diseases (CVD), 
Cancer, Diabetes and Chronic Lung Diseases are the 04 main NCDs. The concept of Polypill (multiple active 
pharmaceutical ingredients in tablet or capsule) or Polycap has  gained broader acceptance now a day by  the vision of 
clutch of research groups  in the context of  secondary prevention from CVD of NCDs.  In 2003, Professor Nicholas 
Wald &  Malcolm Law  provided evidence for the  potential efficacy of  poly pill to prevent it from CVD by more 
than 80% to all adults over 55 and to adults of any age with one CVD risk factors  by comprising a low-dose aspirin , 
folic acid , a potent statin with standard dose (eg, atorvastatin or simvastatin), and three  BP-lowering drugs at half the 
standard dose (among thiazide diuretics, β-blockers, ACE inhibitors, ARBs, and calcium channel) .Several study trial 
have been conducted but uptil now The Indian Polycap Study (TIPS) over 2000 subjects without cardiovascular disease, 
is the only published & first  completed trial of (03 years period ) Polypill , started   in 2009 that  tests primarily the 
feasibility and pharmacological effects of various polypill preparations  to assess the efficacy and safety in a formulation 
of  3 common antihypertensive drugs (thiazide (12.5 mg), atenolol (50 mg), ramipril (5 mg) along with aspirin(100mg) 
and a statin (20mg) per day combined in Polycap.  It’s a timely need in Pakistan too to take an advantage of concept of 
poly pill & must conduct a study due to higher death rate by CVD.
Reference:
	 l Non communicable diseases –country profile,2011 Available at: www.who.int/nmh/publications/ncd_profiles_report.pdf
	 l The Indian Polycap Study (TIPS); Effects of a polypill (Polycap) on risk factors in middle-aged individuals without 
  cardiovascular disease (TIPS): a phase II, double-blind, randomised trial; The Lancet; Volume 373, Issue 9672, 18–24 
  April 2009, Pages 1341–1351..
Dengue Vaccine - Hope for Future
Dr Azeem Iftikhar, Pharmacist
Dengue is one of the endemic infection in Pakistan and most prevalent after monsoon season. WHO recommends 
that countries should consider introduction of the dengue vaccine CYD-TDV only in geographic settings (national or 
subnational) where epidemiological data indicate a high burden of disease. The first dengue vaccine, Dengvaxia (CYD-
TDV) by one of the pharmaceutical manufacturer, was first registered in Mexico in December, 2015. CYD-TDV is a live 
recombinant tetravalent dengue vaccine that has been evaluated as a 3-dose series on a 0, 6 and 12 month schedule in Phase 
III clinical studies. It has been registered for use in individuals of 09 - 45 years of age living in endemic areas. The safety 
profile was considered good, and there was no indication of more severe dengue disease in breakthrough cases in vaccine 
recipients that occurred over the 25 months of active case surveillance. Post marketing surveillance reports shows it to 
be effective for young school going children’s and adults. Its side effects and precautions are similar to that of other live 
vaccines. Let’s hope to prevent the dengue infections by vaccination and adapting preventive measures.
References:
	 l Dengue virus infection prevention and treatment; Available at: www.uptodate.com
	 l Dengue vaccine: WHO position paper – July 2016. Weekly epidemiological record 2016; 91(30): 349–64.
